ARTICLE
17 May 2016

Judge Sleet Concludes That Defendants Did Not Prove Invalidity Of Asserted Claim In ANDA Action

FR
Fox Rothschild LLP

Contributor

Who We Are

With bold growth, Fox Rothschild brings together 1,000 attorneys coast to coast. We offer the reach and resources of a national law firm combined with the personal touch and connections of a boutique firm.

Our Mission

Solving problems is our top priority. We invest the time to get to know you and understand your needs. We work hard to win every client’s loyalty. We do that by providing creative solutions and excellent client service.

The Court issued its findings of fact and conclusions of law pursuant to Federal Rule of Civil Procedure 52(a).
United States Intellectual Property

Following a four day bench trial in a consolidated ANDA action before The Honorable Gregory M. Sleet in Genzyme Corp., et al. v. Dr. Reddy's Laboratories, Ltd., et al., Civil Action Nos. 13-1506 and 13-1508-GMS (D.Del., May 11, 2016), the Court issued its findings of fact and conclusions of law pursuant to Federal Rule of Civil Procedure 52(a) and specifically concluded that Defendants failed to establish by clear and convincing evidence that claim 19 of U.S. Patent No. 7,897,590 ("the '590 patent") is invalid due to obviousness.

A copy of the Memorandum setting forth the Court's findings of fact and conclusions of law is attached.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More